Yes I agree. They may not have released it because OS takes longer to collate, (the patients may still be alive) so they don't have the data. I was struck by the way they added this into their release
"This secondary study endpoint is important as liver tumours are commonly the only, or dominant, site of disease in patients with mCRC and are the major site of disease influencing survival. Up to 90% of mCRC patients die of liver failure due to the local effects of the liver tumours"
(This is not investment advice. When considering an investment make sure to speak to someone more qualified than I am.)
SRX Price at posting:
$17.53 Sentiment: Hold Disclosure: Held
